437 related articles for article (PubMed ID: 27304054)
1. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
3. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
4. [Cancer stem cells in colon cancer].
Pannequin J
Bull Cancer; 2017 Dec; 104(12):1072-1074. PubMed ID: 29153380
[No Abstract] [Full Text] [Related]
5. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
6. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.
Garson K; Vanderhyden BC
Reproduction; 2015 Feb; 149(2):R59-70. PubMed ID: 25301968
[TBL] [Abstract][Full Text] [Related]
7. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
8. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Ahmed N; Abubaker K; Findlay J; Quinn M
Curr Cancer Drug Targets; 2010 May; 10(3):268-78. PubMed ID: 20370691
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer stem cell markers: prognostic and therapeutic implications.
Burgos-Ojeda D; Rueda BR; Buckanovich RJ
Cancer Lett; 2012 Sep; 322(1):1-7. PubMed ID: 22334034
[TBL] [Abstract][Full Text] [Related]
11. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
12. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
Steg AD; Bevis KS; Katre AA; Ziebarth A; Dobbin ZC; Alvarez RD; Zhang K; Conner M; Landen CN
Clin Cancer Res; 2012 Feb; 18(3):869-81. PubMed ID: 22142828
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
Bhattacharya R; Mitra T; Ray Chaudhuri S; Roy SS
J Cell Biochem; 2018 Apr; 119(4):3373-3383. PubMed ID: 29130517
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
15. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
Mirza S; Jain N; Rawal R
Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.
Dia VP; Pangloli P
J Cell Physiol; 2017 Feb; 232(2):391-401. PubMed ID: 27198989
[TBL] [Abstract][Full Text] [Related]
17. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
[TBL] [Abstract][Full Text] [Related]
18. Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress.
Ip CK; Li SS; Tang MY; Sy SK; Ren Y; Shum HC; Wong AS
Sci Rep; 2016 Jun; 6():26788. PubMed ID: 27245437
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.
Mihanfar A; Aghazadeh Attari J; Mohebbi I; Majidinia M; Kaviani M; Yousefi M; Yousefi B
J Cell Physiol; 2019 Apr; 234(4):3238-3253. PubMed ID: 30317560
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.
Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM
J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
